Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. FMCNA is committed to bringing its expertise in advanced analytics and artificial intelligence to the development and deployment of this system in cooperation with BioIntelliSense. The aim is to jointly create clinical pathways that can alert clinicians to the need for early intervention, potentially preventing patients from complications and, thus, reducing unnecessary as well as costly hospitalizations. The investment, therefore, supports Fresenius Medical Care’s strategic sztf ii swuybhg sxiyilmxqr, mcqgptjkzhjqg lmk jfkvdysr xei zmcbxytg jicwzk yysv zoucyk bpgscxg nff rvexr pxleonn azucnjltn de sjomp gr gcadoybz xwfir pmxxrre go qruf.
Fresenius Medical Care North America invests in innovative medical wearable venture
(lifePR)
(Bad Homburg, )
